Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection

References

• Zain J, Bhagat G, O’Connor OA. Mantle cell lymphoma. In: Armitage JO, Mauch PM, Harris NL, et al., editors. Non-Hodgkin lymphomas. Philadelphia: Lippincott Williams & Wilkins; 2009. pp 284–301.
   Google Scholar
• Pileri SA, Falini B. Mantle cell lymphoma. Haematologica 2009;94:1488–1492.
   PubMed Web of Science ®Google Scholar
• Hartmann E, Fernandez V, Moreno V, et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008;26:4966–4972.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009:542–551.
   Google Scholar
• Williams ME, Meeker TC, Swerdlow SH. Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes. Blood 1991;78:493–498.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000;95:619–626.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185–197.
   PubMed Web of Science ®Google Scholar
• Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006;107:3407.
   PubMed Web of Science ®Google Scholar
• Tucker CA, Bebb G, Klasa RJ, et al. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res 2006;30:449–457.
   PubMed Web of Science ®Google Scholar
• Goy A, Remache YK, Gu J, et al. Establishment and characterization of a new mantle cell lymphoma cell line M-1. Leuk Lymphoma 2004;45:1255–1260.
   PubMed Web of Science ®Google Scholar
• Camps J, Salaverria I, Garcia MJ, et al. Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res 2006;30:923–934.
   PubMed Web of Science ®Google Scholar
• O’Connor OA. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. Curr Treat Options Oncol 2004;5:269–281.
   PubMedGoogle Scholar
• O’Connor OA. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 2005;6:191–199.
   PubMedGoogle Scholar
• O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676–684.
   PubMed Web of Science ®Google Scholar
• Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007;13:5291–5294.
   PubMed Web of Science ®Google Scholar
• Cecconi D, Zamo A, Parisi A, et al. Induction of apoptosis in Jeko-1 mantle cell lymphoma cell line by resveratrol: a proteomic analysis. J Proteome Res 2008;7:2670–2680.
   PubMed Web of Science ®Google Scholar
• Peponi E, Drakos E, Reyes G, et al. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006;169:2171–2180.
   PubMed Web of Science ®Google Scholar
• Xiao H, Zhang KJ, Xia B. Defects of FA/BRCA pathway in lymphoma cell lines. Int J Hematol 2008;88:543–550.
   PubMed Web of Science ®Google Scholar
• Hay RJ. The seed stock concept and quality control for cell lines. Anal Biochem 1988;171:225–27.
   PubMed Web of Science ®Google Scholar
• Melo JV, Foroni L, Brito-Babapulle V, et al. The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement. Clin Exp Immunol 1988;73:23–28.
   PubMed Web of Science ®Google Scholar
• Lai R, McDonnell TJ, O’Connor SL, et al. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res 2002;26:849–855.
   PubMed Web of Science ®Google Scholar
• Estrov Z, Talpaz M, Ku S, et al. Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leuk Res 1998;22:341–353.
   PubMed Web of Science ®Google Scholar
• Melo JV, Brito-Babapulle V, Foroni L, et al. Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Int J Cancer 1986;38:531–538.
   PubMed Web of Science ®Google Scholar
• Raynaud SD, Bekri S, Leroux D, et al. Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies. Genes Chromosomes Cancer 1993;8:80–87.
   PubMed Web of Science ®Google Scholar
• Saltman DL, Cachia PG, Dewar AE, et al. Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1) with a chromosomal (11:14) translocation [t(11:14)(q13;q32)]. Blood 1988;72:2026–2030.
   PubMed Web of Science ®Google Scholar
• Jeon HJ, Kim CW, Yoshino T, et al. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol 1998;102:1323–1326.
   PubMed Web of Science ®Google Scholar
• Zamo A, Ott G, Katzenberger T, et al. Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma. Haematologica 2006;91:40–47.
   PubMed Web of Science ®Google Scholar
• Abe M, Nozawa Y, Wakasa H, et al. Characterization and comparison of two newly established Epstein-Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability. Cancer 1988;61:483–490.
   Google Scholar
• Daibata M, Takasaki M, Hirose S, et al. Establishment of a new human B cell line carrying t(11;14) chromosome abnormality. Jpn J Cancer Res 1987;78:1182–1185.
   PubMedGoogle Scholar
• Drexler HG, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of mantle cell lymphoma. Leuk Res 2002;26:781–787.
   PubMed Web of Science ®Google Scholar
• Daibata M, Kubonishi I, Eguchi T, et al. The establishment of Epstein-Barr virus nuclear antigen-positive (SP-50B) and Epstein-Barr virus nuclear antigen-negative (SP-53) cell lines with t(11;14)(q13;q32) chromosome abnormality from an intermediate lymphocytic lymphoma. Cancer 1989;64:1248–1253.
   PubMed Web of Science ®Google Scholar
• Rudolph C, Steinemann D, Von Neuhoff N, et al. Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519. Cancer Genet Cytogenet 2004;153:144–150.
   PubMedGoogle Scholar
• M’Kacher R, Farace F, Bennaceur-Griscelli A, et al. Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model. Cancer Genet Cytogenet 2003;143:32–38.
   PubMed Web of Science ®Google Scholar